Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;62(8):827-840.
doi: 10.1007/s00108-021-01059-0. Epub 2021 Jun 18.

[Diagnostics and treatment of statin-associated muscle symptoms]

[Article in German]
Ursula Kassner, Stefanie Grunwald, Dominik Spira, Nikolaus Buchmann, Thomas Bobbert, Elisabetta Gazzerro, Tim Hollstein, Simone Spuler, Elisabeth Steinhagen-Thiessen  1
Affiliations
Review

[Diagnostics and treatment of statin-associated muscle symptoms]

[Article in German]
Ursula Kassner et al. Internist (Berl). 2021 Aug.

Abstract
in English, German

Statins are among the most frequently prescribed drugs in Germany. Their benefits in lowering cardiovascular risk are beyond dispute. Nevertheless, many patients complain of side effects from statin therapy, including statin-associated muscle symptoms (SAMS) in particular. Despite their relative frequency, it is difficult to objectively diagnose them, as the time until appearance of first symptoms, the nature of the complaints and the severity of muscle problems vary widely. This narrative review summarizes the causes of SAMS as well as new possibilities regarding their diagnosis and therapy.

Statine zählen zu den am häufigsten verordneten Medikamenten deutschlandweit. Ihr Nutzen in der Senkung des kardiovaskulären Risikos ist unbestritten. Dennoch klagen viele Patienten über Nebenwirkungen unter Statintherapie, wozu insbesondere statinassoziierte Muskelsymptome (SAMS) zählen. Diese sind trotz ihrer relativen Häufigkeit schwer zu erfassen und objektiv zu diagnostizieren, da der Zeitraum bis zum ersten Auftreten von Symptomen, die Art der Beschwerden und der Schweregrad der Muskelprobleme sehr stark variieren. In diesem narrativen Review werden die Ursachen der SAMS sowie neue Möglichkeiten zur Diagnostik und Therapie zusammengefasst.

Keywords: Creatine kinase; Genetic predisposition to disease; HMG CoA reductase; Myalgia; Myopathies.

PubMed Disclaimer

References

Literatur

    1. Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2:517–526 - PubMed - DOI - PMC
    1. WHO (Hrsg) (2016) Global health estimates 2016: deaths by cause, age, sex, by country and by region, 2000–2016. World Health Organization, Geneva
    1. Laufs U, Scharnagl H, Halle M, Windler E, Endres M, März W (2015) Behandlungsoptionen bei Statin-assoziierten Muskelbeschwerden. Dtsch Arztebl Int 112:748–755 - PubMed - PMC
    1. Schmidt N, Dressel A, Grammer TB, Gouni-Berthold I, Julius U, Kassner U, Klose G, König C, Koenig W, Otte B, Parhofer KG, Reinhard W, Schatz U, Schunkert H, Steinhagen-Thiessen E, Vogt A, Laufs U, März W (2018) Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: the CaReHigh Registry. Atherosclerosis 277:314–322 - PubMed - DOI - PMC
    1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M‑R, Tokgozoglu L, Wiklund O, Mueller C, Drexel H, Aboyans V, Corsini A, Doehner W, Farnier M, Gigante B, Kayikcioglu M, Krstacic G, Lambrinou E, Lewis BS, Masip J, Moulin P, Petersen S, Petronio AS, Piepoli MF, Pintó X, Räber L, Ray KK, Reiner Ž, Riesen WF, Roffi M, Schmid J‑P, Shlyakhto E, Simpson IA, Stroes E, Sudano I, Tselepis AD, Viigimaa M, Vindis C, Vonbank A, Vrablik M, Vrsalovic M, Zamorano JL, Collet J‑P, Koskinas KC, Casula M, Badimon L, John Chapman M, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M‑R, Tokgozoglu L, Wiklund O, Windecker S, Aboyans V, Baigent C, Collet J‑P, Dean V, Delgado V, Fitzsimons D, Gale CP, Grobbee D, Halvorsen S, Hindricks G, Iung B, Jüni P, Katus HA, Landmesser U, Leclercq C, Lettino M, Lewis BS, Merkely B, Mueller C, Petersen S, Petronio AS, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Sousa-Uva M, Touyz RM, Nibouche D, Zelveian PH, Siostrzonek P, Najafov R, Van De Borne P, Pojskic B, Postadzhiyan A, Kypris L, Špinar J, Larsen ML, Eldin HS, Viigimaa M, Strandberg TE, Ferrières J, Agladze R, Laufs U, Rallidis L, Bajnok L, Gudjónsson T, Maher V, Henkin Y, Gulizia MM, Mussagaliyeva A, Bajraktari G, Kerimkulova A, Latkovskis G, Hamoui O, Slapikas R, Visser L, Dingli P, Ivanov V, Boskovic A, Nazzi M, Visseren F, Mitevska I, Retterstøl K, Jankowski P, Fontes-Carvalho R, Gaita D, Ezhov M, Foscoli M, Giga V, Pella D, Fras Z, De Isla LP, Hagström E, Lehmann R, Abid L, Ozdogan O, Mitchenko O, Patel RS: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020;41:111–188

Substances

LinkOut - more resources